Advertisement

Current HIV/AIDS Reports

, Volume 12, Issue 3, pp 344–352 | Cite as

Emerging Challenges in Managing Hepatitis B in HIV Patients

  • Vincent SorianoEmail author
  • Pablo Labarga
  • Carmen de Mendoza
  • José M. Peña
  • José V. Fernández-Montero
  • Laura Benítez
  • Isabella Esposito
  • Pablo Barreiro
Co-infections and Comorbidity (S Naggie, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Co-infections and Comorbidity

Abstract

Roughly 10 % of HIV-positive individuals worldwide have concomitant chronic hepatitis B virus (HBV) infection, with large differences between geographical regions and/or risk groups. Hepatitis B is a preventable infection with vaccines. However, it cannot be eradicated once acquired, resembling HIV and in contrast with HCV. In developed countries, hepatitis B exhibits particular features in the HIV population. First, HBV infection is less frequently misdiagnosed than in the general population. Second, nucleos(t)ide analogs active against HBV are widely used as part of antiretroviral combinations and are taken by most HIV patients. Lastly, as the HIV population ages given the success of antiretroviral therapy, non-AIDS co-morbidities are becoming a major cause of disease, for which specific drugs are required, increasing the risk of interactions and hepatotoxicity. Furthermore, concern on HBV reactivation is rising as immunosuppressive drug therapies are increasingly been used for cancers and other non-malignant conditions. In this scenario, new challenges are emerging in the management of hepatitis B in HIV-positive individuals. Among them, major interest is focused on failures to suppress HBV replication, HBV breakthroughs and reactivations, the meaning of isolated anti-HBc, screening for liver cancer, and the complexity arising when hepatitis viruses C and/or D are additionally present. This review will focus on these challenges and the major advances in HBV coinfection in HIV.

Keywords

HBV Hepatitis B HIV Coinfection Tenofovir Lamivudine Drug resistance Hepatitis delta Vaccine 

Notes

Compliance with Ethics Guidelines

Conflict of Interest

Vincent Soriano declares a grant from Instituto de Salud Carlos III for projects ICI14-00372, CES12/003, PI13/01574) and a grant from Fundacion Investigacion y Educacion en SIDA.

Pablo Labarga, Carmen de Mendoza, José M. Peña, José V. Fernández-Montero, Laura Benítez, Isabella Esposito, and Pablo Barreiro declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance

  1. 1.
    Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-Hepatitis B virus international panel. AIDS. 2008;22:1399–410.PubMedCrossRefGoogle Scholar
  2. 2.
    Thio C. Hepatitis B, and Human immunodeficiency virus coinfection. Hepatology. 2009;49(suppl):138–45.CrossRefGoogle Scholar
  3. 3.
    Soriano V, de Mendoza C, Fernandez-Montero JV, Labarga P, Barreiro P. Management and treatment of chronic hepatitis B in HIV-positive patients. Ann Med. 2014;46:290–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Kellerman S, Hanson D, McNaghten A, Fleming P. Prevalence of chronic hepatitis B and incidence of acute hepatitis B infection in HIV-infected participants. J Infect Dis. 2003;188:571–7.PubMedCrossRefGoogle Scholar
  5. 5.
    Konopnicki D, Mocroft A, de Wit S, et al. Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort. AIDS. 2005;19:2117–25.CrossRefGoogle Scholar
  6. 6.•
    WHO. Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. March 2015 (www.who.int) This document is an updated comprehensive report on the prevention, management and treatment of hepatitis B, with special focus on developing regions. Non-invasive methods for assessing liver fibrosis are overtly recommended instead of liver biopsies whereas tenofovir or entecavir are preferred over lamivudine as HBV therapy.
  7. 7.•
    Modi A, Feld J. Viral hepatitis and HIV in Africa. AIDS Rev. 2007;9:25–39. This is one of the most comprehensive reviews on the epidemiology of viral hepatitis in Africa and its overlap with the HIV epidemic.Google Scholar
  8. 8.
    Geretti AM, Patel M, Sarfo F, et al. Detection of highly prevalent HBV co-infection among HIV-seropositive persons in Ghana. J Clin Microbiol. 2010;48:3223–30.PubMedCentralPubMedCrossRefGoogle Scholar
  9. 9.
    Chun H, Fieberg A, Hullsied K, et al. Epidemiology of Hepatitis B virus infection in a US cohort of HIV-infected individuals during the past 20 years. Clin Infect Dis. 2010;50:426–36.PubMedCentralPubMedCrossRefGoogle Scholar
  10. 10.
    Te H, Jensen D. Epidemiology of hepatitis B and C viruses: a global overview. Clin Liver Dis. 2010;14:1–21.PubMedCrossRefGoogle Scholar
  11. 11.
    Trepo C, Chan H, Lok A. Hepatitis B virus infection. Lancet. 2014;384:2053–63.PubMedCrossRefGoogle Scholar
  12. 12.
    European AIDS Clinical Society Guidelines. Version 7.0. October 2013. Available at http://www.europeanaidsclinicalsociety.org. Accessed on April 27th 2015.
  13. 13.
    DHHS. Recommendations for use of antiretroviral drugs in HIV-1-infected adults and adolescents. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/.pdf. Accessed on April 27th 2015.
  14. 14.
    Gunthard H, Aberg J, Eron J, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the International Antiviral Society-USA panel. JAMA. 2014;312:410–25.PubMedCrossRefGoogle Scholar
  15. 15.•
    Thio C, Seaberg E, Skolasky R, et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet. 2002;360:1921–6. This is a pivotal study demonstrating that HIV worsts the natural history of chronic hepatitis B.Google Scholar
  16. 16.
    Buti M, Tsai N, Petersen J, Flisiak R, Gurel S, Krastev Z, et al. Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. Dig Dis Sci (in press).Google Scholar
  17. 17.•
    Martín-Carbonero L, Teixeira T, Poveda E, et al. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS. 2011;25:73–9. This study reports HBV outcomes in one of the largest series of HIV-HBV coinfected individuals followed for the longest follow-up on tenofovir-containing regimens.Google Scholar
  18. 18.
    Koklu S, Tuna Y, Gulsen M, et al. Long-term efficacy and safety of lamivudine, entecavir, and tenofovir for treatment of hepatitis B virus-related cirrhosis. Clin Gastroenterol Hepatol. 2013;11:88–94.PubMedCrossRefGoogle Scholar
  19. 19.•
    Boyd A, Gozlan J, Maylin S, et al. Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long-term tenofovir: virological and clinical implications. Hepatology. 2014;60:497–507. This study reported a 10% rate of low-level HBV-DNA in 111 HIV-HBV coinfected patients treated with tenofovir and followed for more than 6 years.Google Scholar
  20. 20.
    Sheldon J, Camino N, Rodes B, et al. Selection of hepatitis B virus polymerase mutations in HIV coinfected patients treated with tenofovir. Antivir Ther. 2005;10:727–34.PubMedGoogle Scholar
  21. 21.
    Liu Y, Fung S, Gane E, et al. Evaluation of HBV-DNA decay kinetics in patients containing both rtM204V/I mutant and wild-type HBV subpopulations during tenofovir DF (TDF) monotherapy or combination therapy with emtricitabine (FTC)/TDF. J Med Virol. 2014;86:1473–81.PubMedCrossRefGoogle Scholar
  22. 22.
    Fung S, Kwan P, Fari M, et al. Randomized comparison of tenofovir vs emtricitabine and tenofovir in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology. 2014;146:980–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Corsa A, Liu Y, Flaherty J, et al. No resistance to tenofovir disoproxil fumarate through 96 weeks of treatment in patients with lamivudine-resistant chronic hepatitis B. Clin Gastroenterol Hepatol (in press).Google Scholar
  24. 24.
    Plaza Z, Aguilera A, Mena A, et al. Influence of HIV infection on response to tenofovir in patients with chronic hepatitis B. AIDS. 2013;27:2219–24.PubMedCrossRefGoogle Scholar
  25. 25.
    Boyd A, Moh R, Gabillard D, et al. Low risk of lamivudine-resistant HBV and hepatic flares in treated HIV-HBV co-infected patients from Cote d’Ivoire. Antivir Ther 2015 (in press).Google Scholar
  26. 26.
    Hoffmann C, Charalambous S, Martin D, et al. Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis. 2008;47:1479–85.PubMedCentralPubMedCrossRefGoogle Scholar
  27. 27.
    Soriano V, Rivas P, Nuñez M. Risks and benefits of using antiretroviral therapy in HIV-infected patients with chronic hepatitis B in developing regions. Clin Infect Dis. 2008;47:1486–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Thibault V, Aubron-Olivier C, Agut H, Katlama C. Primary infection with a lamivudine-resistant hepatitis B virus. AIDS. 2002;16:131–3.PubMedCrossRefGoogle Scholar
  29. 29.
    Tuma P, Pineda J, Labarga P, et al. HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain. Antivir Ther. 2011;16:585–89.PubMedCrossRefGoogle Scholar
  30. 30.
    Kouanfack C, Aghokeng A, Mondain A, et al. Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon. Antivir Ther. 2012;17:321–6.PubMedCrossRefGoogle Scholar
  31. 31.
    Velasco M, Morán A, Téllez MJ. Resolution of chronic hepatitis B after ritonavir treatment in an HIV-infected patient. N Engl J Med. 1999;340:1765–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Crane M, Oliver B, Matthews G, Avihingsanon A, Ubolyam S, Markovska V, et al. Immunopathogenesis of hepatic flare in HIV/HBV-coinfected individuals after the initiation of HBV-active antiretroviral therapy. J Infect Dis. 2009;199:974–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Soriano V, Puoti M, Garcia-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS. 2008;22:1–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Dore G, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857–65.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Berg T, Simon K, Mauss S, Schott E, Heyne R, Klass D, et al. Stopping tenofovir treatment after long-term virologic suppression in HBeAg-negative CHB: week 48 interim results from an ongoing randomized, controlled trial (FINITE CHB) [abstract O-119]. J Hepatol. 2015;62(suppl):253.CrossRefGoogle Scholar
  36. 36.
    Labarga P, Barreiro P, Martin-Carbonero L, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS. 2009;23:689–96.PubMedCrossRefGoogle Scholar
  37. 37.
    Del Palacio M, Romero S, Casado JL. Proximal tubular renal dysfunction or damage in HIV-infected patients. AIDS Rev. 2012;14:179–87.PubMedGoogle Scholar
  38. 38.
    Rifkin B, Perazella M. Tenofovir-associated nephrotoxicity: Fanconi syndrome and renal failure. Am J Med. 2004;117:282–4.PubMedCrossRefGoogle Scholar
  39. 39.
    Karras A, Lafaurie M, Furco A, et al. Tenofovir-related nephrotoxicity in HIV-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis. 2003;36:1070–3.PubMedCrossRefGoogle Scholar
  40. 40.
    Bedimo R, Maalouf N, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS. 2012;26:825–31.PubMedCrossRefGoogle Scholar
  41. 41.
    Wands J, Chura C, Roll F, et al. Serial studies of hepatitis-associated antigen and antibody in patients receiving antitumor chemotherapy for myeloproliferative and lymphoproliferative disorders. Gastroenterology. 1975;68:105–12.Google Scholar
  42. 42.•
    Perrillo R, Martin P, Lok A. Preventing hepatitis B reactivation due to immunosuppressive drug regimens. JAMA (in press). This editorial briefly updates which circumstances may prone to hepatitis B reactivation and how to prevent it.Google Scholar
  43. 43.
    Yeo W, Johnson P. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology. 2006;43:209–20.PubMedCrossRefGoogle Scholar
  44. 44.
    Seto W, Chan T, Hwang Y, Wong D, Liu K, Gill H, et al. A prospective study of hepatitis B reactivation in patients with prior HBV exposure undergoing hematopoietic stem cell transplantation: reactivation association with graft-versus-host disease [abstract O-009]. J Hepatol. 2015;62(suppl):194.CrossRefGoogle Scholar
  45. 45.
    Milazzo L, Ebranati E, Cattaneo D, et al. Recurrence of another hepatitis B virus escape mutant comes back in a patient infected with HIV and low CD4+ count. J Med Virol. 2014;86:97–101.PubMedCrossRefGoogle Scholar
  46. 46.
    Pei R, Grund S, Verheyen J, Esser S, Chen X, Lu M. Spontaneous reactivation of hepatitis B virus replication in an HIV coinfected patient with isolated anti-hepatitis B core antibodies. Virol J. 2014;11:9.PubMedCentralPubMedCrossRefGoogle Scholar
  47. 47.
    Soriano V, McMahon B. Strategic use of lamivudine in the management of chronic hepatitis B. Antivir Res. 2013;100:435–8.PubMedCrossRefGoogle Scholar
  48. 48.•
    McMahon B, Jilek B, Brennan T, et al. The HBV drug entecavir—effects on HIV-1 replication and resistance. N Engl J Med. 2007;356:2614–21. This was the first report of the unexpected weak antiretroviral effect of entecavir and the risk for selection of drug resistance mutations in HIV.Google Scholar
  49. 49.
    Koskinas J, Tampaki M, Doumba P, Rallis E. Hepatitis B virus reactivation during therapy with ustekinumab for psoriasis in a HBsAg-negative anti-HBs + patient. Br J Dermatol. 2013;168:679–80.PubMedCrossRefGoogle Scholar
  50. 50.
    López-Serrano P, de la Fuente E, Carrera E, Pérez-Calle J, Fernández C. Hepatitis B and immunosuppressive therapies for chronic inflammatory diseases: when and how to apply prophylaxis, with a special focus on corticosteroid therapy. World J Hepatol. 2015;7:539–47.PubMedCentralPubMedCrossRefGoogle Scholar
  51. 51.
    Tamori A, Koike T, Goto H, Wakitani S, Tada M, Morikawa H, et al. Prospective study of reactivation of HBV in patients with rheumatoid arthritis who received immunosuppressive therapy: evaluation of both HBsAg-positive and HBsAg-negative cohorts. J Gastroenterol. 2011;46:556–64.PubMedCrossRefGoogle Scholar
  52. 52.
    Lok A, McMahon B. Chronic hepatitis B: update 2009. Hepatology. 2009;50:661–96.PubMedCrossRefGoogle Scholar
  53. 53.
    Lok A. Personalized treatment of hepatitis B. Clin Mol Hepatol. 2015;21:1–6.PubMedCentralPubMedCrossRefGoogle Scholar
  54. 54.
    Kane M. Global programme for control of hepatitis B infection. Vaccine. 1995;13(suppl):47–9.CrossRefGoogle Scholar
  55. 55.
    World Health Organization. Hepatitis B vaccines: WHO position paper. Wkly Epidemiol Rec. 2009;84:405–19.Google Scholar
  56. 56.
    Rivas P, Herrero MD, Puente S, Ramírez-Olivencia G, Soriano V. Immunizations in HIV-infected adults. AIDS Rev. 2007;9:173–87.PubMedGoogle Scholar
  57. 57.
    Fonseca M, Pang L, de Paula-Cavalheiro N, Barone A, Heloisa-Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. Vaccine. 2005;23:2902–8.PubMedCrossRefGoogle Scholar
  58. 58.
    Launay O, van der Vliet D, Rosenberg A, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. JAMA. 2011;305:1432–40.PubMedCrossRefGoogle Scholar
  59. 59.
    Roni D, Pathapati R, Kumar A, Nihal L, Sridhar K, Tumkur RS. Safety and efficacy of hepatitis B vaccination in cirrhosis of liver. Adv Virol. 2013;20:196704.Google Scholar
  60. 60.
    Witt M, Lewis R, Rieg G, Seaberg E, Rinaldo C, Thio C. Predictors of the isolated hepatitis B core antibody pattern in HIV-infected and -uninfected men in the multicenter AIDS cohort study. Clin Infect Dis. 2013;56:606–12.PubMedCentralPubMedCrossRefGoogle Scholar
  61. 61.
    Gandhi R, Wurcel A, Lee H, et al. Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: implications for hepatitis B vaccine strategies. J Infect Dis. 2005;191:1435–41.PubMedCrossRefGoogle Scholar
  62. 62.
    Wang Q, Semmo N. T and B cell responses and previous exposure to hepatitis B virus in “anti-HBc alone” patients [abstract O-010]. J Hepatol. 2015;62(suppl):194–5.CrossRefGoogle Scholar
  63. 63.
    Locarnini S, Hatzakis A, Chen D, Lok A. Strategies to control hepatitis B: public policy, epidemiology, vaccine and drugs. J Hepatol. 2015;62(suppl):76–86.CrossRefGoogle Scholar
  64. 64.
    Whitaker J, Rouphael N, Edupuganti S, Lai L, Mulligan M. Strategies to increase responsiveness to hepatitis B vaccination in adults with HIV-1. Lancet Infect Dis. 2012;12:966–76.PubMedCentralPubMedCrossRefGoogle Scholar
  65. 65.•
    Chen C, Yang H, Su J, et al. Risk of hepatocellular carcinoma across biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295:65–73. This manuscript derives from the REVEAL-HBV study and reported for the first time a strong positive direct correlation between baseline serum HBV-DNA and the risk of liver cancer in chronic hepatitis B patients.Google Scholar
  66. 66.
    Wu C, Lin J, Ho H, Su C, Lee T, Wang S, et al. Association of nucleoside analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B—a nationwide cohort study. Gastroenterology. 2014;147:143–51.PubMedCrossRefGoogle Scholar
  67. 67.
    Clifford G, Rickenbach M, Polesel J, et al. Influence of HIV-related immunodeficiency on the risk of hepatocellular carcinoma. AIDS. 2008;22:2135–41.PubMedCrossRefGoogle Scholar
  68. 68.
    Fernández-Montero JV, Soriano V. Management of hepatitis C in HIV and/or HBV co-infected patients. Best Pract Res Clin Gastroenterol. 2012;26:517–30.PubMedCrossRefGoogle Scholar
  69. 69.
    Zhou J, Dore G, Zhang F, Lim P, Chen Y, Asia TREAT, et al. Hepatitis B and C virus coinfection in the TREAT Asia Observational database. J Gastroenterol Hepatol. 2007;22:1510–8.PubMedCrossRefGoogle Scholar
  70. 70.
    Pontisso P, Ruvoletto M, Fattovich G, Chemello L, Callorini A, Ruol A, et al. Clinical and virological profiles in patients with multiple hepatitis virus infections. Gastroenterology. 1993;105:1529–33.PubMedCrossRefGoogle Scholar
  71. 71.
    Chu C, Lee S. Hepatitis B virus/hepatitis C virus coinfection: epidemiology, clinical features, viral interactions and treatment. J Gastroenterol Hepatol. 2008;23:512–20.PubMedCrossRefGoogle Scholar
  72. 72.
    Soriano V, Barreiro P, Martin-Carbonero L, et al. Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis. J Infect Dis. 2007;195:1181–3.PubMedCrossRefGoogle Scholar
  73. 73.
    Liu C, Chen P, Lai M, Kao J, Jeng Y, Chen D. Ribavirin and interferon is effective for hepatitis C virus clearance in hepatitis B and C dually infected patients. Hepatology. 2003;37:568–76.PubMedCrossRefGoogle Scholar
  74. 74.
    Liu C, Chuang W, Lee C, et al. Peginterferon alfa-2b plus ribavirin for the treatment of dual chronic infection with hepatitis B and C viruses. Gastroenterology. 2009;136:496–504.PubMedCrossRefGoogle Scholar
  75. 75.•
    Collins J, Raphael K, Terry C, et al. Hepatitis B reactivation during successful treatment of hepatitis C with sofosbuvir and simeprevir. Clin Infect Dis (in press) This study records for the first time two cases of HBV reactivation during successful DAA therapy for hepatitis C.Google Scholar
  76. 76.
    Wedemeyer H, Heidrich B, Manns M. Hepatitis D virus infection – not a vanishing disease in Europe! Hepatology. 2007;45:1331–2.PubMedCrossRefGoogle Scholar
  77. 77.
    Soriano V, Grint D, d’Arminio-Monforte A, et al. Hepatitis delta in HIV-infected individuals in Europe. AIDS. 2011;25:1987–92.PubMedCrossRefGoogle Scholar
  78. 78.
    Calle-Serrano B, Manns M, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis. 2012;32:120–9.PubMedCrossRefGoogle Scholar
  79. 79.
    Kew M. Hepatitis viruses (other than hepatitis B and C viruses) as causes of hepatocellular carcinoma: an update. J Viral Hepat. 2013;20:149–57.PubMedCrossRefGoogle Scholar
  80. 80.
    Farci P, Niro G. Clinical features of hepatitis D. Semin Liver Dis. 2012;32:228–36.PubMedCrossRefGoogle Scholar
  81. 81.•
    Fernández-Montero JV, Vispo E, Barreiro P, Sierra-Enguita R, de Mendoza C, Labarga P, et al. Hepatitis delta is a major determinant of liver decompensation events and death in HIV-infected patients. Clin Infect Dis. 2014;58:1549–53. This large study highlights the deleterious impact of hepatitis delta on HIV-positive individuals in comparison with coinfection with other hepatitis viruses (B and C).Google Scholar
  82. 82.
    Erhardt A, Gerlich W, Starke C, et al. Treatment of chronic hepatitis D with pegylated interferon-alpha 2b. Liver Int. 2006;26:805–10.PubMedCrossRefGoogle Scholar
  83. 83.
    Yurdaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis. 2012;32:237–44.PubMedCrossRefGoogle Scholar
  84. 84.
    Farci P, Roskams T, Chessa L, et al. Long-term benefit of interferon as therapy of chronic hepatitis D: regression of advanced hepatic fibrosis. Gastroenterology. 2004;126:1740–9.PubMedCrossRefGoogle Scholar
  85. 85.
    Niro G, Ciancio A, Gaeta G, et al. Pegylated interferon alpha-2b as monotherapy or in combination with ribavirin in chronic hepatitis D. Hepatology. 2006;44:713–20.PubMedCrossRefGoogle Scholar
  86. 86.
    Yurdaydin C, Bozkaya H, Onder F, et al. Treatment of chronic D hepatitis with lamivudine vs lamivudine + interferon vs interferon. J Viral Hepat. 2008;15:314–21.PubMedCrossRefGoogle Scholar
  87. 87.
    Wedemeyer H, Yurdaydìn C, Dalekos G, HIDIT Study Group, et al. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011;364:322–31.PubMedCrossRefGoogle Scholar
  88. 88.
    Wedemeyer H, Port K, Heidrich S, et al. 96 weeks of pegylated interferon alpha-2a plus tenofovir or placebo for the treatment of hepatitis delta: the HIDIT-2 study. Washington DC: AASLD; 2013 [abstract 31].Google Scholar
  89. 89.
    Mansour W, Ducancelle A, Le Gal F, et al. Resolution of chronic hepatitis Delta after 1 year of combined therapy with pegylated interferon, tenofovir and emtricitabine. J Clin Virol. 2010;47:97–9.PubMedCrossRefGoogle Scholar
  90. 90.
    James G, Sidhu P, Raza M. First report of successful clearance of hepatitis B and D coinfection with tenofovir monotherapy. Hepatology (in press).Google Scholar
  91. 91.
    Sheldon J, Ramos B, Toro C, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther. 2008;13:97–102.PubMedGoogle Scholar
  92. 92.
    Soriano V, Vispo E, Sierra-Enguita R, et al. Efficacy of prolonged tenofovir therapy on hepatitis delta in HIV-infected patients. AIDS. 2014;28:2389–94.PubMedCrossRefGoogle Scholar
  93. 93.
    Soriano V, Barreiro P, de Mendoza C. Tenofovir for hepatitis delta. Hepatology (in press).Google Scholar
  94. 94.
    Farci P. Treatment of chronic hepatitis D: new advances, old challenges. Hepatology. 2006;44:536–9.PubMedCrossRefGoogle Scholar
  95. 95.
    Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis. 2012;32:245–55.PubMedCrossRefGoogle Scholar
  96. 96.
    Ni Y, Lempp F, Mehrle S, et al. Hepatitis B and D viruses exploit sodium taurocholate co-transporting polypeptide for species-specific entry into hepatocytes. Gastroenterology. 2014;146:1070–83.PubMedCrossRefGoogle Scholar
  97. 97.
    Zoulim F, Durantel D. Antiviral therapies and prospects for a cure of chronic hepatitis B. Cold Spring Harb Perspect Med. 2015;5:a021501.PubMedCrossRefGoogle Scholar
  98. 98.
    Yurdaydin C, Idilman R, Choong I, et al. Optimizing the prenylation inhibitor lonafarnib using ritonavir boosting in patients with chronic delta hepatitis. EASL, Vienna, April 2015 [abstract O118]. J Hepatol. 2015;62(suppl):252.CrossRefGoogle Scholar
  99. 99.
    Schirmera P, Wintersb M, Holodniy M. HIV-HBV vaccine escape mutant infection with loss of HBV surface antibody and persistent HBV viremia on tenofovir/emtricitabine without antiviral resistance. J Clin Virol. 2011;52:261–4.CrossRefGoogle Scholar
  100. 100.
    Pal A, Sarkar N, Saha D, et al. High incidence of lamivudine-resistance associated vaccine-escape HBV mutant among HIV-coinfected patients on prolonged antiretroviral therapy. Antivir Ther (in press).Google Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Vincent Soriano
    • 1
    Email author
  • Pablo Labarga
    • 2
  • Carmen de Mendoza
    • 3
  • José M. Peña
    • 1
  • José V. Fernández-Montero
    • 4
  • Laura Benítez
    • 3
  • Isabella Esposito
    • 1
  • Pablo Barreiro
    • 1
  1. 1.Infectious Diseases UnitLa Paz University HospitalMadridSpain
  2. 2.Department of Internal Medicine, La Luz ClinicMadridSpain
  3. 3.Department of Internal MedicinePuerta de Hierro Research Institute & University HospitalMadridSpain
  4. 4.Department of Infectious DiseasesCrosshouse University HospitalKilmarnock, ScotlandUK

Personalised recommendations